HC Wainwright Has Weak Estimate for Invivyd FY2024 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share estimates for shares of Invivyd in a research note issued on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($1.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Other equities analysts have also issued research reports about the stock. Morgan Stanley decreased their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Price Performance

Invivyd stock opened at $0.70 on Friday. Invivyd has a fifty-two week low of $0.69 and a fifty-two week high of $5.20. The firm’s 50 day simple moving average is $0.97 and its 200-day simple moving average is $1.23. The company has a market cap of $83.90 million, a P/E ratio of -0.36 and a beta of 0.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. XTX Topco Ltd raised its holdings in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares in the last quarter. SG Americas Securities LLC boosted its position in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new position in Invivyd in the second quarter valued at about $86,000. Finally, Rhumbline Advisers increased its position in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.